ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients

Ahmed Daouda Department of Internal Medicine, Cairo University Kasr Alainy Faculty of Medicine, Cairo, Egypt

Hatem Alib Department of Internal Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Internal Medicine, Coventry, United Kingdom of Great Britain and Northern Ireland

Vinaya Raoc Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA

Vinayak Rohand Department of Surgery, Medical University of South Carolina, Charleston, SC, USA

Karim Solimanc Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USACorrespondence[email protected]

References

Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B. 2021;11(1):1–12.
PubMed Web of Science ®Google Scholar
Jarcho JA, Ingelfinger JR, Hamel MB, et al. Inhibitors of the renin-angiotensin-aldosterone system and covid-19. N Engl J Med. 2020;382(25):2462–2464.
PubMed Web of Science ®Google Scholar
Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681.
PubMed Web of Science ®Google Scholar
Hsu CM, Weiner DE, Aweh G, et al. COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider. Am J Kidney Dis. 2021;77(5):748–756.e1.
PubMed Web of Science ®Google Scholar
Sánchez-Alvarez E, Macía M, de Sequera Ortiz P. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective from the Spanish nephrology. Kidney360. 2020;1(11):1254–1258.
PubMedGoogle Scholar
Lano G, Braconnier A, Bataille S, et al. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre french cohort. Clin Kidney J. 2020;13(5):878–888.
PubMed Web of Science ®Google Scholar
Hilbrands LB, Duivenvoorden R, Vart P, ERACODA Collaborators, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–1983.
PubMed Web of Science ®Google Scholar

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date